News & Updates

Adding bevacizumab to an EGFR tyrosine kinase inhibitor (TKI) improves overall survival (OS) in adult patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LMs), according to a single-centre, retrospective, real-world study in China. OS was, however, similar between patients on chemotherapy plus EGFR-TKI and those on EGFR-TKI monotherapy.

Patients with hepatitis B virus (HBV) infection are at heightened risk of latent tuberculosis (TB), while those with latent TB are also at increased risk of HBV infection, reveals a study. Notably, the risk of co-infection is highest among Asians and those born in high-incidence countries.

Long COVID may have contributed to reduced participation in the UK labour market, a cohort study suggests.

Remdesivir may cut the risk of symptoms and diagnoses associated with possible post-COVID conditions (PCC), otherwise known as long COVID.

A negative affective state can aggravate dyspnoea in patients with chronic obstructive pulmonary disease (COPD), a study has shown. This suggests that reducing the likelihood of negative mood or improving the mood can help in managing morbidities associated with dyspnoea in COPD.

Breakthrough COVID-19 is not uncommon following pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs), reports a recent study. However, most of the infections in this high-risk population are not severe.

Patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) who received a pulse dose of corticosteroids do not appear to have longer survival than those who received conventional nonpulse dose of corticosteroids, results of a study have shown.

In a study presented at AAAAI 2024, epinephrine in preservative-free, nasal powder formulations demonstrated superior stability and comparable plasma exposure to the EpiPen^® autoinjector, thus providing a less-invasive treatment option for severe allergic reactions including anaphylaxis.

Omalizumab scores in the NIH*-sponsored phase III OUtMATCH** trial, increasing the threshold for an allergic reaction to peanut and other common food allergens in children and adults with multiple food allergies.